Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
- Resource Type
- Article
- Authors
- Bachelard, Antoine; Hingrat, Quentin Le; Ferré, Valentine-Marie; Lê, Minh; Peytavin, Gilles; Damond, Florence; Charpentier, Charlotte; Goudot, Guillemette Fremont; Bouille, Jeanne Goupil de; Lariven, Sylvie; Delobel, Pierre; Yazdanpanah, Yazdan; Descamps, Diane; Matheron, Sophie; Ghosn, Jade; group, for the ANRS CO05 VIH-2 cohort study
- Source
- Clinical Infectious Diseases. 4/15/2024, Vol. 78 Issue 4, p1005-1010. 6p.
- Subject
- *THERAPEUTIC use of monoclonal antibodies
*KIDNEY function tests
*PATIENT compliance
*VIRAL load
*RESEARCH funding
*SALVAGE therapy
*SCIENTIFIC observation
*DRUG resistance in microorganisms
*CD4 lymphocyte count
*MULTIDRUG resistance
*HIV infections
*TREATMENT effectiveness
*BLOOD cell count
*DESCRIPTIVE statistics
*ANTIVIRAL agents
*COMBINED modality therapy
*RESEARCH
*BLOOD plasma
*ANTI-HIV agents
*DRUGS
*GENETIC mutation
*TIME
*LIVER function tests
*DRUG tolerance
- Language
- ISSN
- 1058-4838
We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation. [ABSTRACT FROM AUTHOR]